#Novamind subscription trial#

#Novamind subscription trial#

The results of this trial definitively demonstrate MORE's sustained efficacy for treating opioid misuse.ĭr.

He was awarded the University of Utah's 'Distinguished Professor' award for his contributions to the field, which include the largest randomized controlled trial of MORE to date. Garland is a world-leading expert on the use of mind-body therapies to address opioid misuse and addiction in people with chronic pain. Participants will undergo eight weeks of treatment with MORE therapy plus two KAP sessions at Novamind's Murray, Utah research site in early 2022.ĭr. The hope is that ketamine will enhance the benefits of buprenorphine for this difficult-to-treat condition when paired with MORE, a proven psychological intervention developed by Dr. The MORE+KAP Clinical Trial, led by lead investigator Eric Garland, PhD, LCSW at the University of Utah, is the first to investigate the effects of intramuscular KAP for adult outpatients treated with buprenorphine, a first-line medication for opioid use disorder. Recent studies have shown promise for the use of ketamine in treating substance use disorders, including alcohol and cocaine use disorders.1,2 With opioid-related deaths continuing to rise across nearly all populations age 15 and older,3the MORE+KAP Clinical Trial comes at a critical time and makes an important contribution to the early evidence base for effective treatment options. The study will investigate the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy (the 'MORE+KAP Clinical Trial'). (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, today announced it will host a phase I randomized clinical trial for adults with opioid use disorder. TORONTO, ON / ACCESSWIRE / Janu/ Novamind Inc.